13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674546
Total reported value
$4.8B
$4.8B
169 檔
31.9%
In Q1 2024, Bellevue Group AG's U.S. equity holdings reached a combined market value of $4.8B, distributed across 169 disclosed stock positions.
During Q1 2024, Bellevue Group AG's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including IONS, ARGX, NBIX) accounted for 31.9% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 5.49% | -1.63% | -4.76% | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.87% | +0.44% | -6.69% | |
| 3 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 4.32% | +0.08% | -15.41% | |
| 4 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 4.26% | -1.20% | -9.19% | |
| 5 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 4.15% | -1.01% | -18.01% | |
| 6 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.29% | -1.39% | -0.69% | |
| 7 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.98% | — | -8.05% | |
| 8 | MRNA | Moderna Inc | Stock-Healthcare | 2.78% | — | -10.34% | |
| 9 | DXCM | Dexcom Inc | Stock-Healthcare | 2.58% | -0.01% | +33.52% | |
| 10 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.49% | +0.56% | -0.34% | |
| 11 | ABT | Abbott Laboratories | Stock-Healthcare | 2.49% | -1.00% | -6.61% | |
| 12 | SYK | Stryker CORP | Stock-Healthcare | 2.45% | +0.08% | -3.52% | |
| 13 | MGNX | Macrogenics Inc | Stock-Other | 2.24% | — | +0.13% | |
| 14 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.09% | -1.84% | +3.72% | |
| 15 | INCY | Incyte CORP | Stock-Healthcare | 1.87% | — | -0.15% | |
| 16 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.79% | +0.03% | +15.74% | |
| 17 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.79% | — | -0.12% | |
| 18 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.61% | -0.19% | +8.26% | |
| 19 | BDX | Becton Dickinson And Co | Stock-Healthcare | 1.57% | -0.11% | +7.12% | |
| 20 | ARVN | Arvinas Inc | Stock-Other | 1.51% | — | -4.66% | |
| 21 | MDT | Medtronic plc | Stock-Healthcare | 1.34% | -0.33% | +3.73% | |
| 22 | SG7 | Sage Therapeutics Inc | Stock-Other | 1.28% | — | +27.10% | |
| 23 | EXK | Exact Sciences CORP | Stock-Materials | 1.20% | — | +8.66% | |
| 24 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.12% | +0.35% | +7.65% | |
| 25 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 1.10% | — | +1.99% | |
| 26 | EPIEUR | Essa Pharma Inc | Stock-Other | 1.02% | — | -0.11% | |
| 27 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.96% | -0.15% | -0.39% | |
| 28 | BHVN | Biohaven Ltd. | Stock-Other | 0.96% | — | +6.98% | |
| 29 | OPCH | Option Care Health Inc | Stock-Healthcare | 0.96% | — | -3.69% | |
| 30 | CRL | Charles River Laboratories | Stock-Healthcare | 0.95% | — | +5.48% | |
| 31 | INSM | Insmed Inc | Stock-Healthcare | 0.89% | +3.09% | -6.51% | |
| 32 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.83% | — | +7.89% | |
| 33 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 0.83% | — | +10.96% | |
| 34 | HCA | Hca Healthcare Inc | Stock-Healthcare | 0.81% | -0.24% | +4.94% | |
| 35 | ELV | Elevance Health Inc | Stock-Healthcare | 0.78% | +0.09% | -8.51% | |
| 36 | ALGN | Align Technology Inc | Stock-Healthcare | 0.77% | -0.07% | -2.82% | |
| 37 | IDXX | Idexx Laboratories Inc | Stock-Healthcare | 0.77% | -0.51% | -0.80% | |
| 38 | PODD | Insulet CORP | Stock-Healthcare | 0.77% | -0.41% | +1.35% | |
| 39 | ACCDUSD | Accolade Inc | Stock-Other | 0.77% | — | +6.59% | |
| 40 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.75% | +0.59% | -0.16% | |
| 41 | EVH | Evolent Health Inc - A | Stock-Other | 0.74% | — | -37.61% | |
| 42 | HUM | Humana Inc | Stock-Healthcare | 0.72% | +0.22% | +34.90% | |
| 43 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.71% | -0.12% | EXIT | |
| 44 | GEHC | GE Healthcare Technology | Stock-Healthcare | 0.71% | -0.37% | -4.29% | |
| 45 | EXEL | Exelixis Inc | Stock-Healthcare | 0.69% | — | -9.72% | |
| 46 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.69% | +0.01% | +3.12% | |
| 47 | PRCT | Procept Biorobotics CORP | Stock-Other | 0.67% | -0.06% | +0.54% | |
| 48 | BDTX | Black Diamond Therapeutics I | Stock-Other | 0.66% | — | -0.21% | |
| 49 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.64% | — | -31.15% | |
| 50 | CDNA | Caredx Inc | Stock-Other | 0.64% | — | -0.53% |
According to official SEC Form 13F filings, Bellevue Group AG reported a total U.S. public equity portfolio value of $4.8B across 169 disclosed positions in Q1 2024.
During Q1 2024, Bellevue Group AG's top holdings by market value included IONS (5.5%)、ARGX (4.9%)、NBIX (4.3%). The largest single position, IONS, represented 5.5% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q1 2024, Bellevue Group AG made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.